- Uwe Röhrhoff, former Chief Executive Officer at Gerresheimer AG, appointed President, CEO and board member effective January 15, 2018
- Experienced, customer-centric CEO whose strategic actions and focus on operational excellence transformed Gerresheimer AG and delivered total shareholder return of approximately 225%(1) during his 7-year tenure as CEO
- Proven track record of driving growth and profitability while managing a complex operating platform in global healthcare markets
- Experienced public Board member, including service as Audit Committee Chairman of Catalent, Inc. and Deputy Chairman of Klöckner&Co SE
- John T. Hendrickson to remain with the Company until March 15, 2018 to ensure successful transition
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced the appointment of Uwe Röhrhoff as Chief Executive Officer, effective January 15, 2018, following the retirement of John T. Hendrickson.
Perrigo Chairman Laurie Brlas commented, "The Board of Directors is excited to announce the appointment of Uwe as President and Chief Executive Officer. He is an experienced, well-respected and successful CEO. Uwe brings a strong track record of operational excellence, strategic growth, and healthcare supply chain management. As the CEO of Gerresheimer AG, a publicly-traded international manufacturer for the global pharmaceutical and healthcare industries, Uwe's transformative strategic vision and focus on operational excellence enhanced the company's leading market positions and created significant value for shareholders of approximately 225%1 in total shareholder return as CEO. We are confident that his leadership style and industry, financial and operational expertise are the right fit for Perrigo. We are grateful to John for his passionate leadership and contributions to the Company over the past 28 years. John has been a trusted leader, a great colleague, and a friend to many, and we value his continued guidance as Uwe transitions into his new role."
Mr. Röhrhoff has more than 25 years of experience with Gerresheimer AG, a leading global manufacturer of pharmaceutical packaging products and medical devices for storage, dosage and safe administration of drugs that generated approximately €1.4 billion in revenue in 2016. He began his career with Gerresheimer AG in 1991, steadily advancing within the organization to serve in a number of key leadership roles in Europe and North America. Mr. Röhrhoff was appointed to build out the Company's business in the United States (1996-1998) and head the American subsidiary Gerresheimer Glass Inc. (2001-2010). He served as anexecutive board member (2003-2017), responsible for two of the company's three business units, and CEO (2010-2017) of Gerresheimer AG until his retirement in August 2017. Mr. Röhrhoff, brings with him an extensive operational track record. He led an organization that included 36 manufacturing facilities across 14 countries, delivering products to 1,500 customers, including the 10 largest global pharmaceutical companies, in nearly 100 countries. Mr. Röhrhoff was instrumental in determining Gerresheimer AG's strategic focus, transforming and reshaping the corporate portfolio and delivering on operational projects.
Mr. Röhrhoff serves as Audit Committee Chairman on the Board of Directors of Catalent, Inc., a global provider of drug delivery technology and development solutions for drugs, biologics and consumer health products. He is also Deputy Chairman of Klöckner&Co SE, one of the world's largest producer-independent steel and metal distributors. Mr. Röhrhoff plans to step down from both boards. He earned a business administration degree from the University of Cologne.
Commenting on the opportunities ahead for Perrigo, Mr. Röhrhoff said, "I am excited for the opportunity at Perrigo. I look forward to working with Perrigo's experienced management team, who have been instrumental in positioning the Company's consumer OTC and prescription pharmaceutical businesses to capitalize on current trends in the market. I have long admired Perrigo's operational excellence and its mission to deliver high-quality, affordable healthcare products that improve the lives of patients and families. I see great opportunity to leverage the Company's unique asset base and to lead its talented employees to deliver enhanced value for shareholders. Perrigo's core values resonate with me deeply, and I look forward to leading this organization into its next stage of evolution."
Mr. Hendrickson will resign as CEO and board member on January 15, 2018and will remain with the Company until March 15, 2018 to ensure a smooth and successful transition.